Japan’s CRO CMIC partnered with Bluenote to deploy agentic AI across protocol development, statistical planning and study reports, aiming to accelerate regulatory documentation by up to 75% per company statements. The Blackstone‑backed CRO said the system provides traceability, validation guardrails and automated quality review designed to meet ICH, FDA, PMDA and EMA standards. CMIC positioned the move as part of a broader transformation into a technology‑driven CRO, while Bluenote emphasized regulatory alignment and scaled deployment. The partnership signals growing commercial application of agentic AI in clinical development workflows but will face validation and compliance scrutiny from global regulators.